Literature DB >> 18940572

History of immunoglobulin replacement.

Martha M Eibl1.   

Abstract

The provision of antibodies to prevent and treat infection began with the application of "curative serum" in the first years of the last century. After the process of large-scale plasma fractionation was developed in the 1940s, the general use of immunoglobulin expanded. Intravenous immunoglobulin products became available in the 1970s, and their only use for the provision of antibodies governed the opinion of experts over the next decade. Modulation of inflammation and immunosuppression were introduced in treatment of inflammatory and autoimmune diseases and became accepted indications. The history of adverse events of treatment and their management are outlined in this article. Consensus indications and evidence-based off-label uses are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940572     DOI: 10.1016/j.iac.2008.06.004

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  37 in total

Review 1.  Plasma-derived medicines: access and usage issues.

Authors:  Albert Farrugia; Josephine Cassar
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

Review 2.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 3.  Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Authors:  Hassan Abolhassani; Mohammad Salehi Sadaghiani; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2012-06-23       Impact factor: 8.317

4.  SCIg vs. IVIg: let's give patients the choice!

Authors:  K Samaan; M C Levasseur; H Decaluwe; C St-Cyr; H Chapdelaine; A Des Roches; E Haddad
Journal:  J Clin Immunol       Date:  2014-06-03       Impact factor: 8.317

5.  Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

Authors:  Jeffrey S Stonebraker; Albert Farrugia; Benjamin Gathmann; Jordan S Orange
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 6.  The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative.

Authors:  Albert Farrugia; Giuliano Grazzini; Isabella Quinti; Fabio Candura; Samantha Profili; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

7.  Pattern of intravenous immunoglobulins (IVIG) use in a pediatric intensive care facility in a resource limited setting.

Authors:  Nermeen M Galal
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

8.  Immunoglobulin: production, mechanisms of action and formulations.

Authors:  Marcia Cristina Zago Novaretti; Carla Luana Dinardo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

9.  Thromboembolic complications of intravenous immunoglobulin (IVIG) in an immunocompromised patient with Chronic Lymphocytic Leukemia: a case report.

Authors:  Cannon Milani; Samir M Dalia; Gerald A Colvin
Journal:  Cases J       Date:  2009-11-23

10.  Optimization of immunoglobulin substitution therapy by a stochastic immune response model.

Authors:  Marc Thilo Figge
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.